Cash Flow Statement

Amortization of Deferred Charges Amortization of Deferred Charges Amortizatization of Intangibles Amortizatization of Intangibles Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Cash Depreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and Depletion Depreciation and Depletion Exchange Rate Effect Exchange Rate Effect Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Long-Term Debt Issuances Net Cash Flow Net Cash Flow Net Income Other Working Capital Changes Other Working Capital Changes Other financing activities Other financing activities Preferred Shares Issued Sales of Property, Plant and Equipment Sales of Property, Plant and Equipment Share-based Compensation Share-based Compensation Shares Issued

Daily Values

Growth Metrics

Others

Accumulated Depreciation & Amortization Accumulated Depreciation & Amortization Cost of Revenue EBIAT Gross Profit Leases Long-Term Debt Issuances Machine, Furnitures, Fixtures & Other Other Gross PP&E Adjustments Other Gross PP&E Adjustments Preferred Shares Issued Property, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - Net Receivables - Other Shares Issued Shares Outstanding Shares Outstanding

Elicio Therapeutics (ELTX) Shares Issued (2020 - 2026)

Elicio Therapeutics filings provide 4 years of Shares Issued readings, the most recent being $6.9 million for Q4 2023.

On a quarterly basis, Shares Issued rose 10472.31% to $6.9 million in Q4 2023 year-over-year; TTM through Dec 2023 was $7.0 million, a 8435.37% increase, with the full-year FY2025 number at $16.2 million, up 41551.28% from a year prior.
Shares Issued hit $6.9 million in Q4 2023 for Elicio Therapeutics, up from $127000.0 in the prior quarter.
In the past five years, Shares Issued ranged from a high of $110.6 million in Q1 2021 to a low of -$110.5 million in Q2 2021.
Median Shares Issued over the past 4 years was $65000.0 (2022), compared with a mean of $8.9 million.
The widest YoY moves for Shares Issued: up 11055900.0% in 2021, down 11047900.0% in 2021.
Elicio Therapeutics' Shares Issued stood at $713000.0 in 2020, then soared by 14972.37% to $107.5 million in 2021, then tumbled by 99.94% to $65000.0 in 2022, then soared by 10472.31% to $6.9 million in 2023.
The last three reported values for Shares Issued were $6.9 million (Q4 2023), $127000.0 (Q3 2023), and $65000.0 (Q4 2022) per Business Quant data.